A new venture capital firm located in the USA East Coast focuses on life science companies that develop enabling tools, technologies and services for discovery, development and manufacturing of biologics and related therapies. The firm is focused on early stage venture and growth equity investments. Typical equity investments range from $500k-$5 million. The firm expects to make 6-10 investments in the coming 18 months and is open to either leading or following in a financing round. The firm is currently seeking opportunities from the US, Canada, and Europe.
Within life sciences, the firm is specifically focused on tools, technologies and services that enable the discovery, development and production of life-saving therapies and deliver on the biopharmaceutical industry’s evolution towards lower costs, and increased access to medicines globally. Examples may include immunotherapy, bioinformatics, RNA therapy, synthetic biology. The firm considers Seed- to Series A/B- stage opportunities.
The firm partners with entrepreneurs and their teams to overcome inflection points in growth. The firm takes a hands-on approach to working with its portfolio companies through focused operational and commercial guidance and an engaged approach to supporting entrepreneurial ventures.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply